Trial Profile

A Phase II Study of the Ningetinib in Advanced NSCLC With MET Exon 14 Skipping Mutations

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 19 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ningetinib (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Sunshine Lake Pharma

Most Recent Events

14 May 2026 Status changed from not yet recruiting to withdrawn prior to enrolment.
04 May 2022 Planned End Date changed from 12 Nov 2025 to 9 Dec 2024.
04 May 2022 Planned primary completion date changed from 12 Nov 2025 to 9 Sep 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com